Carfilzomibas/ciklofosfamidas deksametazonas atsakas į I-os eilės gydymą
VISTA trial VMP -CR30% ->PR71%
OS CCD &MPV (VISTA) Šalutinės reakcijos ŠIRDIES NEPAKANKAMUMAS, MIOKARDO INFARKTAS, IŠEMIJA (7 -2 -1 %)
In clinical studies with Kyprolis, cardiac failure was reported in approximately 7% of subjects, MI was reported in approximately 2% of subjects and myocardial ischaemia was reported in approximately 1% of subjects. These events typically occurred early in the course of Kyprolis therapy (< 5 cycles).
DUSULYS (30%)
Dyspnoea was reported in approximately 30% of subjects in clinical studies with Kyprolis. The majority of dyspnoea adverse reactions were non-serious (< 5% of subjects had grade ≥ 3 events), resolved, rarely resulted in treatment discontinuation, and had an onset early in the course of study (< 3 cycles).
HIPERTENZIJA IR HIPERTENZINĖS KRIZĖS (20%)
Hypertensive crises (hypertensive urgency or hypertensive emergency) have occurred following administration of Kyprolis. Some of these events have been fatal. In clinical studies, hypertension adverse events occurred in approximately 20% of subjects and approximately 6% of subjects had grade ≥ 3 hypertension events, but hypertensive crises occurred in < 0.5% of subjects. The incidence of hypertension adverse events was similar between those with or without a prior medical history of hypertension.
Šalutinės reakcijos

TROMBOCITOPENIJA (40%)
Thrombocytopenia was reported in approximately 40% of subjects in clinical studies with Kyprolis and approximately 20% of subjects had grade ≥ 3 events. Kyprolis causes thrombocytopenia through inhibition of platelet budding from megakaryocytes resulting in a classic cyclical thrombocytopenia with platelet nadirs occurring on day 8 or 15 of each 28-day cycle and usually associated with recovery to baseline by the start of the next cycle.
VENŲ TROMBOEMBOLIJA (10,6%)
Cases of venous thromboembolic events, including deep vein thrombosis and pulmonary embolism with fatal outcomes, have been reported in patients who received Kyprolis (see section 4.4). The overall incidence of venous thromboembolic events was higher in the Kyprolis arms of two phase 3 studies. In study 2011 003 the incidence of venous thromboembolic events was 10.6% in the Kd arm and 3.1% in the bortezomib plus dexamethasone (Vd) arm. Grade ≥ 3 venous thromboembolic events were reported in 3.0% of patients in the Kd arm and 1.5% of patients in the Vd arm.
POLINEUROPATIJA (6%)
In a randomised, open-label multicentre study in patients receiving Kyprolis 20/56 mg/m2 infused over 30 minutes in combination with dexamethasone (Kd, n = 464) vs bortezomib plus dexamethasone (Vd, n = 465), cases of grade 2 and higher peripheral neuropathy were reported in 6% compared with 32% in the Vd arm CARFI NMSG#20/13 įtraukimo/atmetimo kriterijai Įtraukimas
• Myeloma diagnosis according to IMWG criteria
• First treatment demanding relapse after HDT
• More than 2.0 x 106 CD34+ stem cells/kg body weight in the freezer for stem cell support
• Signed informed consent given prior to any study related activities have been performed
• Age > 18 years
Atmetimas
• Allogeneic transplantation scheduled as a part of the treatment
• Treatment demanding relapse less than one year after HDT
• Myeloma treatment after the first HDT
• Patients not having received HDT as first line treatment
• Previous treatment with carfilzomib
• Expected survival of less than six months
• Performance status (WHO) 3
• Serum M-component < 5 g/l and urine M-component < 200 mg/l
• Any of the following laboratory abnormalities:
• Serum ALT or AST > 3.5 times, direct bilirubin > 34 μmol/L (2 mg/dL)
• Creatinine clearance (CrCl) < 15 mL/minute.
• Neuropathy rrades 3-4, or grade 2 with pain within 14 days prior to enrolment
• Severe cardiovascular disease ( MI <6 mo, NYHA ≥ III, uncontrolled AP, severe pericardial disease, severe arrhytmias, or cardiac amyloidosis
• LVEF <40%, determined by ECHO or MUGA
• Pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrolment
